MacroGenics (MGNX)
(Delayed Data from NSDQ)
$3.83 USD
-0.17 (-4.25%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $3.82 -0.01 (-0.26%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Brokerage Reports
0 items in cart
MacroGenics, Inc. [MGNX]
Reports for Purchase
Showing records 341 - 360 ( 362 total )
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
Neratinib Highlights Opportunities and Challenges for Margetuximab
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
Competitor''s Breakthrough Therapy Designation Bodes Well for The DART''s
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
MGD006 Becomes First DART to Enter Clinic, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
We initiate with a Buy rating and a $28 price target
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
Transitioning Coverage; MGD010 DART Partnered with Takeda, Reiterate OUTPERFORM while Reducing PT to $52
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
LIFE SCIENCES AND HEALTH CARE: The Week Ahead in Life Sciences - Upcoming Events for the Week of May 5
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: MacroGenics, Inc.
Industry: Medical - Products
Preclinical Data of MGD007 Demonstrate Anti- Tumor Activity in the Colorectal Cancer Setting
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: MacroGenics, Inc.
Industry: Medical - Products
Preclinical Data of MGD007 Demonstrate Anti- Tumor Activity in the Colorectal Cancer Setting
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
ASH Wrap up -- MGD006 pre-clinical oral presentation highlights potency of this CD3 IL-3R DART
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G